Tilikum Therapeutics Overview
- Year Founded
-
2022
- Status
-
Private
- Latest Deal Type
-
Early Stage VC
- Investors
-
1
Tilikum Therapeutics General Information
Description
Developer of inhibitors PARP-1 designed to cure patients with ovarian, breast, and prostate cancers. The company's anti-cancer drug attacks cancer cells in a smaller number of doses, enabling cancer patients to reduce the drug dosage intervals.
Contact Information
Website
tilikumtx.comCorporate Office
- 6 Liberty Square
- Boston, MA 02109-5800
- United States
Corporate Office
- 6 Liberty Square
- Boston, MA 02109-5800
- United States
Tilikum Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC | 01-Jun-2023 | Completed | Startup |
Tilikum Therapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Delin Ventures | Venture Capital | Minority |
Tilikum Therapeutics FAQs
-
When was Tilikum Therapeutics founded?
Tilikum Therapeutics was founded in 2022.
-
Where is Tilikum Therapeutics headquartered?
Tilikum Therapeutics is headquartered in Boston, MA.
-
What industry is Tilikum Therapeutics in?
Tilikum Therapeutics’s primary industry is Drug Discovery.
-
Is Tilikum Therapeutics a private or public company?
Tilikum Therapeutics is a Private company.
-
What is Tilikum Therapeutics’s current revenue?
The current revenue for Tilikum Therapeutics is .
-
Who are Tilikum Therapeutics’s investors?
Delin Ventures has invested in Tilikum Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process